Drug Development
SureNano Science Accelerates Development of Obesity Drug GEP-44, Initiates FDA-Aligned Preclinical Studies
SureNano Science has begun GLP toxicology and pharmacology studies for its lead drug candidate GEP-44, targeting obesity and type 2 diabetes, marking a crucial step toward clinical trials and FDA approval.
Onco-Innovations Advances Manufacturing Process for Cancer Drug Candidate ONC010
Onco-Innovations Limited has initiated process development and scale-up for ONC010's active ingredient, a key step toward regulatory studies and clinical trials.
Optimi Health Completes First Psilocybin Export to UK for Phase 2 Trial
Optimi Health Corp. has exported naturally derived psilocybin to the UK for a planned Phase 2 clinical trial, marking a milestone in international psychedelic drug distribution.
Onco-Innovations Moves Forward with ONC010 Development and Appoints New VP of Corporate Finance
Onco-Innovations has signed a letter of intent with Nanosoft Polymers to advance its oncology candidate ONC010 and appointed Dave Antony as VP of corporate finance, signaling progress in its cancer treatment pipeline.
Kairos Pharma Expands Oncology Pipeline with Proposed Acquisition of Phase 1-Ready c-MET Inhibitor
Kairos Pharma's mid-year update reveals plans to acquire CL-741, a Phase 1-ready oral c-MET inhibitor, expand clinical trials for ENV-105, and secure over $8 million in non-dilutive funding, signaling significant pipeline growth and potential advancements in cancer treatment.
Oncotelic Therapeutics Expands Sapu003 Phase 1b Program with Global CRO Appointment, Signaling Shift to Multinational Development
Oncotelic Therapeutics and Sapu Nano expand the Phase 1b trial for Sapu003, appointing Global Clinical Trials to lead international execution, marking a transition from an Australia-based study to a multinational strategy.
Onco-Innovations Achieves Kilogram-Scale Manufacturing Milestone for Lead Cancer Drug Candidate
Onco-Innovations Limited successfully produced nearly a kilogram of the B4 precursor for its ONC010 PNKP inhibitor, advancing toward clinical trials and scalable production.
Lantern Pharma Reports Phase 2 HARMONIC Trial Data Showing LP-300 Benefit in EGFR-Mutant Lung Cancer
Lantern Pharma announced updated Phase 2 data for LP-300 in EGFR L858R-mutant non-small cell lung cancer, showing improved progression-free survival and a clean safety profile, with an FDA-cleared protocol amendment extending dosing to eight cycles.
Scinai Immunotherapeutics Appoints Eilon Elmalem as Head of Yavne CDMO Facility, Signaling Expansion in Contract Manufacturing
Scinai Immunotherapeutics appoints Eilon Elmalem as site head of its Yavne CDMO facility, underscoring the company's commitment to expanding its contract development and manufacturing platform.
Quantum BioPharma Hits Midpoint Enrollment in MS Imaging Study, Signaling Potential for Novel Diagnostic and Therapeutic Advances
Quantum BioPharma announced that its collaborative MS imaging study with Massachusetts General Hospital has reached midpoint enrollment, with preliminary PET tracer data showing promise for detecting active and gray matter lesions, which could accelerate development of its investigational MS therapy Lucid-MS.
Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker Lung Cancer
Lantern Pharma announced FDA no objections to protocol amendments for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced NSCLC, focusing on a specific EGFR mutation subgroup.
NanoViricides Highlights Broad-Spectrum Antiviral NV-387 Amid Ebola Outbreak
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool amid the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda.
Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Showing Encouraging Early Data
Quantum BioPharma announced that patient enrollment in its multiple sclerosis imaging study with Massachusetts General Hospital has reached 50%, with preliminary PET imaging data showing promising signals in acute MS lesions and potential sensitivity to gray matter lesions, which could accelerate development of MS therapies including its candidate Lucid-MS.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug
NanoViricides announced a $2 million registered direct offering with a single institutional investor, aiming to fund development of its broad-spectrum antiviral NV-387, which targets multiple viruses including COVID-19, influenza, and RSV.
Oncotelic Therapeutics Reports Q1 2026 Results, Highlights Progress in Oncology and AI Drug Development
Oncotelic Therapeutics reported first-quarter 2026 financial results and a corporate update, emphasizing advances in its oncology pipeline, AI-enabled drug development platform, and nose-to-brain CNS delivery system, while maintaining a $388 million valuation of its stake in GMP Biotechnology.
Annovis Bio Achieves 85% Enrollment in Phase 3 Alzheimer’s Trial, Advances Parkinson’s Program
Annovis Bio reports first-quarter progress with 85% enrollment in its pivotal Phase 3 Alzheimer's trial and 40% enrollment in its Parkinson's open-label study, signaling potential regulatory milestones for buntanetap.
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides' quarterly report details progress with NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug designation for measles, highlighting its broad-spectrum antiviral strategy.
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Cancer Drug Development
Lantern Pharma has closed a $4.4 million registered direct offering, providing capital to support its AI-powered oncology pipeline and commercial launch of the Zeta.ai platform.
Kairos Pharma Receives 2026 Healthcare Innovation Award for Drug Resistance Research
Kairos Pharma has been recognized with the 2026 GHP Magazine Healthcare & Pharmaceutical Award as the USA leader in drug resistance development, highlighting its work on cancer therapeutics that address treatment resistance.
GeoVax Highlights Gedeptin's Role in Overcoming Immune Resistance in Cold Tumors
GeoVax Labs emphasizes its Gedeptin platform's potential to enhance checkpoint inhibitor efficacy by modulating the tumor microenvironment, positioning it as a key combination immunotherapy for immunologically cold tumors.
Oncotelic Therapeutics Doses First Patient in Phase 1b Trial of Sapu003 for Advanced Solid Tumors
Oncotelic Therapeutics and Sapu Nano announced the first patient dosed in a Phase 1b trial of Sapu003, an IV formulation of everolimus, aiming to improve delivery and reduce toxicity for advanced mTOR-sensitive solid tumors.
SureNano Science Aims to Overcome GLP-1 Therapy Limitations with Triple Agonist Peptide
SureNano Science Ltd. is developing GEP-44, a triple agonist peptide targeting GLP-1 and PYY receptors, to address efficacy, tolerability, and delivery challenges in the rapidly expanding obesity and metabolic disease market.
OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Capital Reports
Stonegate Capital Partners updates coverage on OS Therapies, highlighting EMA rolling review and TGA endpoint alignment that shift OST-HER2 toward a global approval pathway, with key survival data catalysts in 2026.
SureNano Science Launches IND-Enabling Program for Obesity and Diabetes Drug GEP-44, Targeting a $200 Billion Market
SureNano Science has initiated an FDA-aligned GLP toxicology and pharmacology program for its lead candidate GEP-44, a multi-receptor peptide for obesity and type 2 diabetes, positioning the company to enter the rapidly growing GLP-1 market projected to reach $200 billion by 2030.
SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Lexaria Bioscience Extends Material Transfer Agreement with PharmaCO Through 2026
Lexaria Bioscience has extended its Material Transfer Agreement with an undisclosed pharmaceutical company to evaluate its DehydraTECH technology for GLP-1 drugs, allowing for continued collaboration and review of upcoming R&D results.